On Apr. 22, 2021, Quidel announced that it had completed a distribution and fulfillment agreement with McKesson to expedite consumer access to Quidel’s non-prescription QuickVue At-Home OTC COVID-19 Test.

The agreement with distribution leader McKesson will enable Quidel to continue to supply existing customers in the professional segment and also reach significant new markets as the company introduces its new over-the-counter COVID-19 antigen product for retail markets and testing for reopening schools, and for health departments, employers, entertainment centers, and many other locations. McKesson will be Quidel’s lead commercial partner in fulfilling QuickVue® At-Home OTC COVID-19 rapid antigen test orders to individuals and businesses with the following support:

• Access to multiple retailers, where McKesson will accelerate our product roll-out strategy.
• Availability to McKesson’s Health Mart franchise, allowing Quidel access to a network of over 5,000 independent pharmacies.
• E-commerce support; ability to rapidly introduce products across multiple e-commerce sites, such as Amazon, eBay, and Simply Medical, McKesson’s home health e-commerce site.

The QuickVue® At-Home OTC COVID-19 Test received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in March. The QuickVue® At-Home OTC COVID-19 Test allows consumers to easily perform the test themselves without a doctor’s prescription and get highly accurate results in 10 minutes or less from nasal swab samples. The QuickVue® At-Home OTC COVID-19 Test shows excellent performance, with positive results agreeing with PCR 83.5% of the time, and negative results agreeing 99.2% of the time, delivering confidence to individuals running the test and helping to prevent asymptomatic virus spread.

Shipping of the QuickVue® At-Home OTC COVID-19 Test is expected to begin early next week, and it will be available from McKesson and its customer outlets soon thereafter.